Verona pharma reports strong ohtuvayre™ launch and provides preliminary fourth quarter and full year 2024 financial highlights

Approximately $36 million and $42 million net product sales of ohtuvayre for the fourth quarter and full year 2024, respectively

VRNA Ratings Summary

VRNA Quant Ranking